Ishihara, M., Tono, Y., Miyahara, Y., Muraoka, D., Harada, N., Kageyama, S., . . . Shiku, H. (2020). First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunol Immunother.
Chicago Style CitationIshihara, Mikiya, et al. "First-in-human Phase I Clinical Trial of the NY-ESO-1 Protein Cancer Vaccine With NOD2 and TLR9 Stimulants in Patients With NY-ESO-1-expressing Refractory Solid Tumors." Cancer Immunol Immunother 2020.
MLA CitationIshihara, Mikiya, et al. "First-in-human Phase I Clinical Trial of the NY-ESO-1 Protein Cancer Vaccine With NOD2 and TLR9 Stimulants in Patients With NY-ESO-1-expressing Refractory Solid Tumors." Cancer Immunol Immunother 2020.